by The global EYLEA drug market comprises injectable ophthalmic drugs primarily used for the treatment of neovascular age-related macular degeneration. Some key advantages of EYLEA drugs include reduction of the risk of severe vision loss, limiting the growth of abnormal new blood vessels, and improved vision outcomes compared to alternative treatments. The need for effective drugs to treat back-of-the-eye diseases like age-related macular degeneration is increasing with the growing geriatric population worldwide.
The Global EYLEA Drug Market Size is estimated to be valued at US$ 8.79 Bn in 2024 and is expected to exhibit a CAGR of 7.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the global EYLEA drug market are Bayer, Regeneron Pharmaceuticals, Coherus Biosciences, Inc., And Klinge Biopharma. Bayer And Regeneron Pharmaceuticals Currently Dominate The Market.
Rising prevalence of back-of-the-eye diseases and growing geriatric population globally are projected to drive the demand for EYLEA drugs over the forecast period. Successful clinical trials for expanded indications of EYLEA can further boost the market growth.
Major companies are focusing on geographic expansion and licensing agreements to strengthen their presence in emerging markets and enhance revenue streams. Global players are also pursuing partnerships and acquisitions for novel drugs in development.
Market Key Trends
One of the key trends witnessed in the EYLEA drug market is the approval and launch of expanded indications of EYLEA. In 2021, the FDA approved EYLEA for the treatment of diabetic retinopathy (DR), making it the first anti-VEGF treatment available for this major cause of vision loss. This has led to increased usage of EYLEA and widened the eligible patient pool. This trend of expanded approvals is expected to continue driving the market gains through 2031.
Porter’s Analysis
Threat Of New Entrants: High costs of entry and developing a successful drug deter new companies.
Bargaining Power Of Buyers: Large biopharmaceutical companies have higher negotiating power against small manufacturers.
Bargaining Power Of Suppliers: Suppliers of raw materials have lesser negotiating power as biopharmaceutical companies can switch to alternate suppliers.
Threat Of New Substitutes: While biosimilars pose a threat, EYLEA has established itself as the leading treatment inhibiting growth factors.
Competitive Rivalry: Intense competition exists between Bayer and Regeneron as the major players controlling over 90% market share.
Geographical Regions
North America contributes to over half of the global EYLEA drug market value majorly attributed to rising cases of age-related macular degeneration in the U.S. and Canada. The availability of favorable reimbursement policies for eye care treatment propels the market growth.
Asia Pacific represents the fastest growing regional market and is projected to expand at a CAGR of over 9% during the forecast period. Increasing awareness about eye diseases, development of healthcare infrastructure, and growing discretionary spending on eye care are key factors driving the regional market. The growth trajectory is majorly influenced by China and India attributed to their large patient pools and improving access to advanced treatment options.
What are the key data covered in this Global EYLEA Drug Market report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Global EYLEA Drug Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Global EYLEA Drug Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behavior
:- Global EYLEA Drug Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Global EYLEA Drug Market vendors
FAQ’s
Q.1 What are the main factors influencing the Global EYLEA Drug market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global EYLEA Drug Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global EYLEA Drug market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
- Source: CoherentMI, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
